SS-31 (Elamipretide) vs ARA-290
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
SS-31 (Elamipretide)Immune SupportRecovery & Repair
ARA-290- Summary
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Half-Life
- ~2–5 hours
- ~2–4 hours (SC administration)
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 5–10 mg
- 4 mg (fixed dose)
- Frequency
- Daily to several times per week
- Once daily
- Key Benefits
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Side Effects
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Stacks With
- —
- —